The latest trial results for MDMA-assisted therapy are in—and they are eye-catching.
Existing treatments for posttraumatic stress disorder (PTSD) are few in number and, too often, ineffective. Although still classified as a Schedule I drug, methylenedioxymethamphetamine (MDMA) has improved symptoms PTSD in clinical trials.
In this Mental Health Minute, Tiago Reis Marques, MD, PhD, shares the results of a new phase 3 trial, in which the MDMA-assisted arm of the study outperformed the placebo by 35%. He revisits the history of MDMA and looks to the future, when this Schedule I drug may be approved as a legal treatment.
Dr Marques is a senior clinical fellow on the Faculty of Medicine at Imperial College London, an instructor at the Institute of Psychiatry in King’s College, and the CEO of Pasithea Therapeutics.
Would you prescribe a psychedelic like MDMA? Share comments with your colleagues by emailing PTEditor@mmhgroup.com. Comments may be shared online pending review and editing for style.